Bladder Cancer

>

Latest News

FDA Grants Priority Review to Durvalumab/Chemo in Bladder Cancer
FDA Grants Priority Review to Durvalumab/Chemo in Bladder Cancer

December 6th 2024

The FDA set a Prescription Drug User Fee act date in the second quarter of 2025 for durvalumab plus chemotherapy in muscle-invasive bladder cancer.

Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma
Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

November 20th 2024

Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.
Pembrolizumab/Cisplatin Combo Shows Promise in Small Cell Bladder Cancer, Neuroendocrine Prostate Cancer

November 18th 2024

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.
Extended Lymphadenectomy Does Not Improve DFS/OS in Bladder Cancer

November 6th 2024

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.
Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status

October 29th 2024

<1
...
1415161718